Clinical Trials Logo
  1. Home
  2. Status Epilepticus
  3. NCT05647525
  4. Details
NCT05647525 Clinical Trial

The Etiology of New-onset Status Epilepticus

Status Epilepticus Clinical Trial

Official title:
Sichuan Academy of Medical Sciences - Sichuan Provincial People's Hospital

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05647525
Other study ID # Liujiessy
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date September 30, 2022

Study information
Verified date December 2022
Source Sichuan Provincial People's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This study will help to identify the causes of new epilepsy and provide a basis for the development of a rational and standardized diagnosis and treatment plan to reduce the rate of disability and death.

Recruitment information / eligibility
Status Completed
Enrollment 60
Est. completion date September 30, 2022
Est. primary completion date August 30, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Clinical diagnosis of Status Epilepticus - Sign the informed consent form Exclusion Criteria: - Patients with previous epilepsy - Missing information such as basic information and treatment history - Long-term smoking, alcohol and drug abuse - Pregnant and breastfeeding women

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Perform autoimmune encephalitis titer tests
We only follow up without intervention.

Locations
Country Name City State
China Jie Liu Chengdu Sichuan

Sponsors (1)
Lead Sponsor Collaborator
Jie Liu

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Death 2021-12--2022-12
See also
  Status Clinical Trial Phase
Recruiting NCT03883516 - Improving Emergency Management of Status Epilepticus N/A
Recruiting NCT03378687 - A Clinical Study of Children With Status Epilepticus in China N/A
Recruiting NCT00362141 - Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus Phase 2
Recruiting NCT05140265 - De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information
Active, not recruiting NCT04391569 - Randomized Therapy In Status Epilepticus Phase 3
Recruiting NCT06017973 - The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus N/A
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Recruiting NCT05491590 - Patient-reported Outcome After Status Epilepticus
Recruiting NCT04421846 - Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis N/A
Completed NCT02958605 - Smartphone Apps for Pediatric Resuscitation N/A
Completed NCT02239380 - Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan Phase 3
Completed NCT01796574 - Ketogenic Diet for Refractory Status Epilepticus N/A
Completed NCT02381977 - Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment N/A
Completed NCT00004297 - Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus Phase 3
Completed NCT03905798 - LORA-PITA IV General Investigation
Recruiting NCT05591508 - Ketogenic Diet for Status Epilepticus in Children Post Cessation of Convulsive Status Epilepticus N/A
Completed NCT00735527 - Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children Phase 3
Terminated NCT00265616 - Treatment of Refractory Status Epilepticus Phase 3
Recruiting NCT06401707 - PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest Phase 2
Enrolling by invitation NCT06403150 - The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus Phase 4